Viral reduction techniques: Types and purpose

Transfusion Medicine Reviews

Volumn 15, Issue 2 SUPPL. 1, 2001, Pages 27-39

  Fischer, G ^a   Keith Hoots, W ^a   Abrams, C ^a  

^a Biosynexus Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; SOLVENT;

BLOOD ANALYSIS; CHROMATOGRAPHY; EUROPE; FRACTIONATION; HEAT TREATMENT; PASTEURIZATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; TECHNIQUE; ULTRAFILTRATION; UNITED STATES; VALIDATION PROCESS; VIRUS INACTIVATION;

EID: 0034964628     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tm.2001.25376     Document Type: Review

References (55)

1. Estimates of residual risk in infectious disease transmission during the window period
2. A safer plasma supply from remunerated donors. The immuno/community bioresources experiment
3. Virus safety of prothrombin complex concentrates and factor IX concentrates
4. Acute HIV-1 infection in patients with hemophilia B treated with β-propiolactone-UV-inacfivated clotting factor
5. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissible agents. IUIS Committee on Primary Immunodeficiency Disease
6. BVDV (experimental model for HCV) inactivation by low pH and heat in intravenous human immunoglobulins
7. Safety of human albumin as a constituent of biologic therapeutic products
8. The future of transfusion medicine
9. Virus inactivation of fresh plasma
10. Pasteurized, monoclonal antibody factor VIII concentrate: Establishing a new standard for purity and viral safety of plasma-derived concentrates
11. Detection of TT Virus DNA in Plasma-Derived Clotting Factor Concentrates
12. Viral safety of solvent/detergent-treated plasma
13. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients
14. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center
15. The Italian Collaborative Group. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses
16. An outbreak of hepatitis A among South African patients with hemophilia: Evidence implicating contaminated factor VIII concentrate as the source
17. Hepatitis A virus infections associated with clotting factor concentrate in the United States
18. Large-scale screening for human parvovirus B 19 DNA by PCR: Application to the quality control of plasma for fractionation
19. PCR testing for hepatitis A virus approved
20. Parvovirus B19 PCR testing for Plas + SD. Plas + SD Update
21. Solvent/ detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity
22. Coagulation factor levels in solvent/detergent-treated plasma
23. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
24. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration
25. Value of virus filtration as a method for improving the safety of plasma products
26. Serum and serum substitutes: Virus safety by inactivation or removal
27. Value of virus filtration as a method for improving the safety of plasma products
28. Hepatitis C virus transmission by monoclonal-purified viral-attenuated factor VIII concentrate
29. Hepatitis C and pasteurized factor VIII and IX concentrates
30. Transmission of viral infections through intravenous immune globulins
31. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma
32. Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects
33. Virus reduction in the preparation of intravenous immune globulin: In vitro experiments
34. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate
35. Improving blood safety with light
36. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
37. Food and drug administration: International conference on harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability
38. Blood products
39. Successful clinical use of a plasma-derived, dual virus inactivated factor VIII concentrate incorporating solvent-detergent and dry heat treatment
40. The treatment of blood components with ultraviolet-B irradiation